Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873189 | 0.88 | CCR1 (0.59) | CCR1TSHRTP53LMNAALDH1A1 | |
| SCHEMBL13066688 | 0.84 | CCR1 (0.71) | CCR1 | |
| SCHEMBL13715751 | 0.82 | CCR1 (0.57) | CCR1TSHRL3MBTL1TP53LMNA | |
| SCHEMBL27642598 | 0.81 | CCR1 (0.52) | CCR1TP53MAPTMEN1KMT2A | |
| SCHEMBL27662980 | 0.80 | CCR1 (0.57) | CCR1TP53LMNATHRBALDH1A1 | |
| SCHEMBL2872952 | 0.79 | CCR1 (0.74) | CCR1TP53 | |
| SCHEMBL13715686 | 0.79 | CCR1 (0.58) | CCR1TP53ALDH1A1MAPTMEN1 | |
| SCHEMBL2873980 | 0.79 | CCR1 (0.64) | CCR1TP53LMNATHRBALDH1A1 | |
| SCHEMBL2870322 | 0.79 | CCR1 (0.64) | CCR1TP53LMNATHRBALDH1A1 | |
| SCHEMBL14039628 | 0.79 | CCR1 (0.64) | CCR1TP53LMNATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867336-B | 1-aryl-4-substituted piperazines derivatives and pharmaceutical use thereof | CHEMOCENTRYX INC | 2010-05-12 | — | — | CN | disclosed |
| CN-100542534-C | Substituted piperazines | CHEMOCENTRYX INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| CN-1867336-A | 1-aryl-4-substituted piperazines derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders | CHEMOCENTRYX INC (US) | 2006-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885TSHR 2351/4885L3MBTL1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.